days). The larger the ice-ball produced, the greater the fall in CEA and the slowing of metastatic growth 4 ; however, there are no controlled data to suggest that cryotherapy produces greater survival bene®ts than other forms of interstitial ablation. We agree with Professor Taylor and Dr Gillams that controlled trials of liver resection with thermal ablation are required, but we suggest that a further arm of these trials should include percutaneous cryosurgery. K S Hindle S J Hindle 97 Queen's Drive, Surbiton KT5 8PP, UK REFERENCES 1 Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg 1998;228:201±8 2 Preketes AP, King J, Caplehorn JR, Clingan PR, Ross WB, Morris DL. CEA reduction after cryotherapy for liver metastases from colon cancer predicts survival. Aust N Z J Surg 1994;64:512±14 3 Preketes AP, Caplehorn JR, King J, Clingan PR, Ross WB, Morris DL. Effect of hepatic artery chemotherapy on survival of patients with hepatic metastases from colorectal carcinoma treated with cryotherapy. World J Surg 1995;19:768±71 4 Huang A, Mathur P, McCall J, et al. Dual-probe is more effective than single-probe cryotherapy for hepatic metastases. Br J Cancer 2000;83:45 Research as part of routine care
Sir Iain Chalmers, in his superb editorial drawing attention to the need for evaluative research to become part of routine care in the NHS (November 2000 JRSM, pp. 555±556), identi®es the cultural and attitudinal changes that need to occur if this vision is to be realized, but there remain practical dif®culties.
The ®rst relates to funding. Until evaluation is built into the budget for the introduction of new technologies, it will continue to be dif®cult to secure funding for evaluation on a competitive basis, and even more dif®cult to time this so that the research can take place as the new technology is introduced. This is particularly a problem for service developments and for proper evaluation of changing roles.
Much could be achieved if routinely collected data about health service activity and quality were of suf®cient validity to support health technology assessment. We are shortly to report a study which has sought to identify whether routinely collected data could be used with con®dence in randomized controlled trials, and our preliminary conclusions suggest that they could if the availability and quality of the data could be improved. Improving the situation will, in itself, require culture change, but not a great deal of investment, as the processes for routine collection of data are in place. The problem is that they are under managerial and not clinical ownership and control. Until this changes, matters are unlikely to improve.
